Huang, X.-W.;                     Zheng, H.-X.;                     Wang, M.-L.;                     He, W.-M.;                     Feng, M.-X.;                     Zeng, K.;                     Li, L.    
        Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines 2022, 10, 549.
    https://doi.org/10.3390/vaccines10040549
    AMA Style
    
                                Huang X-W,                                 Zheng H-X,                                 Wang M-L,                                 He W-M,                                 Feng M-X,                                 Zeng K,                                 Li L.        
                Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines. 2022; 10(4):549.
        https://doi.org/10.3390/vaccines10040549
    
    Chicago/Turabian Style
    
                                Huang, Xiao-Wen,                                 Huan-Xin Zheng,                                 Meng-Lei Wang,                                 Wan-Mei He,                                 Mei-Xin Feng,                                 Kang Zeng,                                 and Li Li.        
                2022. "Adalimumab in Treating Refractory Livedoid Vasculopathy" Vaccines 10, no. 4: 549.
        https://doi.org/10.3390/vaccines10040549
    
    APA Style
    
                                Huang, X.-W.,                                 Zheng, H.-X.,                                 Wang, M.-L.,                                 He, W.-M.,                                 Feng, M.-X.,                                 Zeng, K.,                                 & Li, L.        
        
        (2022). Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines, 10(4), 549.
        https://doi.org/10.3390/vaccines10040549